Psychosis during peginterferon-α2a and ribavirin therapy: Case report

Brazilian Journal of Infectious Diseases

Volumn 10, Issue 6, 2006, Pages 406-407

  Quarantini, Lucas C ^a   Cruz, Simone Cunha ^a   Batista Neves, Susana Carolina ^a   Paraná, Raymundo ^a   Miranda Scippa, Ângela ^a   Bressan, Rodrigo A ^b  

^a FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Hepatitis C; Interferon alpha; Psychosis

Indexed keywords

INTERFERON; PEGINTERFERON ALPHA2A; RIBAVIRIN; RISPERIDONE;

ADULT; AGGRESSIVENESS; ARTICLE; CASE REPORT; DELUSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FAMILY HISTORY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MALE; PARANOID PERSONALITY DISORDER; PSYCHOSIS; RETREATMENT; SIDE EFFECT; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PSYCHOSES, SUBSTANCE-INDUCED; RIBAVIRIN; RISPERIDONE;

EID: 34247116963     PISSN: 14138670     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Davis GL. Epidemiology of hepatitis C. BMJ 2001;323: 1141-2.
2. Poynard T., Yuen M-F., Ratziu V., Lung Lai C. Viral hepatitis C. Lancet 2003;362:2095-2100.
3. Hadiyannis S.J., Sette H. Jr., Morgan T.R., et al. Peginterferondá2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-55.
4. Manns M.P., McHutchison J.G., Gordon S.C., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358: 958-65.
5. Dieperink E., Willenbring M., Ho SB. Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: a review, Am J Psychiatry 2000;157:867-76.
6. Schafer M., Boetsch T., Laakmann G. Psychosis in a methadone-substituted patient during interferon-alpha treatment of hepatitis C. Addiction 2000;95:1101-4.
7. D'Innella P., Zaccala G, Terazzi M., et al. Psychotic disorders induced by interferon alfa. Source Recenti Progressi in Medicina 2002; 93:367-9.
8. Kornischka J., Burtscheidt W., Gaebel W. Interferon-induced paranoid psychosis. Review of the literature and case report. Nervenarzt 2002;73:463-7.
9. Tamam L., Yerdelen D., Ozpoyraz N. Psychosis associated with interferon alpha therapy for chronic hepatitis B. Ann Pharmacother 2003; 37:384-7.
10. Rifai M. A., Bozorg B., Rosentein D. L. Interferon for hepatitis C patients with psychiatric disorders. Am J Psychiat 2004; 161:2331-2.
11. Van Thiel D.H., Friedlander L., Molloy P.J., et al. Interferon-alpha can be used successfully in patients with hepatitis C virus-positive chronic hepatitis who have psychiatric illness. Eur J Gastroen Hepat 1995; 7:165-8.
12. Dobmeier M., Frick E., Frank S., et al. Schizophrenic psychosis: a contraindication for treatment of hepatitis C with interferon alpha? Pharmacopsychiatry 2000;33:72-4.
13. Shuto H., Kataoka Y., Horikawa T., et al. Repeated interferon-alpha administration inhibits dopaminergic neural activity in the mouse brain. Brain Res 1997;747:348-51.
14. Raison C.L., Demetrashvili M., Capuron L., Miller A.H. Neuropsychiatric adverse effects of interferon-α: recognition and management. CNS Drugs 2005;19:105-123.
15. Zuckerman L., Rehavi M., Nachman R., Weiner I. Immune activation during pregnancy in rats leads to a postpubertal emergence of disrupted latent inhibition, dopaminergic hyperfunction, and altered limbic morphology in the offspring: a novel neurodevelopmental. model of schizophrenia. Neuropsychopharmacol 2003;28:1778-89.
16. Preble O.T., Torrey E.F. Serum interferon in patients with psychosis. Source American Journal of Psychiatry 1985;142:1184-6.